Zomedica Pharmaceuticals

ZOMPre-clinical

Ann Arbor, United StatesFounded 2012zomedica.com

Zomedica Pharmaceuticals is a veterinary diagnostics and therapeutics company dedicated to advancing companion animal health. Its primary commercial asset is the TRUFORMA® platform, a point-of-care biosensor that enables veterinarians to perform rapid, in-clinic diagnostic testing. The company has transitioned from a development-stage entity to a commercial organization, focusing on expanding its assay menu and driving adoption within veterinary clinics. Zomedica's strategy involves leveraging its platform technology to address significant unmet needs in veterinary endocrinology and other disease areas.

Market Cap

$95.3M

Founded

2012

Employees

50-100

Focus

Biotech

AI Company Overview

Technology Platform

TRUFORMA® point-of-care biosensor platform utilizing Bulk Acoustic Wave (BAW) technology for label-free, rapid, in-clinic diagnostic testing in veterinary medicine.

Funding History

Total raised: $120M

PIPE$75MUndisclosedFeb 15, 2021

Series B$20MUndisclosedDec 15, 2016

IPO$15MUndisclosedDec 15, 2016

Series A$10MUndisclosedJun 15, 2015

Opportunities

Significant growth opportunity lies in expanding the menu of assays on the TRUFORMA® platform into new, high-volume diagnostic areas beyond endocrinology.

Additionally, there is potential for strategic partnerships or distribution agreements to accelerate market penetration and geographic expansion.

Risk Factors

Key risks include intense competition from much larger, established players like IDEXX and Zoetis, slower-than-expected commercial adoption of the TRUFORMA® platform by veterinarians, and potential challenges in successfully developing and launching new assays to drive future growth.

Competitive Landscape

Zomedica competes in the veterinary POC diagnostics market against giants IDEXX and Zoetis. Its primary differentiation is the TRUFORMA® platform's BAW technology, which offers a unique, reagent-stable approach for specific complex tests, rather than competing directly on broad-panel chemistry.